ibi363

Advanced Malignancies

Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 1/2Active

CCC

52/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 40/ 100
Competitive Position: 89/ 100

Competitive context

1411 Active assets in the Advanced Malignancies cohort.

Asset / Sponsor	Phase	Rating
Nabiximols Jazz Pharmaceuticals	Phase 3	BBB
Inno-206 M.D. Anderson Cancer Center	Phase 2	BB
Vitamin B6 M.D. Anderson Cancer Center	Phase 4	BB
PROPOFOL Hong Kong Children's Hospital	Phase 4	BB
Rivoceranib Jiangsu HengRui Medicine Co., Ltd.	Phase 4	BB

View all 50 →

Same molecule, other indications

ibi363 is also rated in:

renal cell carcinomaDormant

CCC

Indicative ·

53 / 100

Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)Dormant

CCC

Indicative ·

53 / 100

EGFR Mutant NSCLC and Platinum Resistant Ovarian CancerDormant

CCC

Indicative ·

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.